Erenumab (AMG 334), a monoclonal antagonist antibody against the canonical CGRP receptor, does not impair vasodilatory or contractile responses to other vasoactive agents in human isolated cranial arteries
Open Access
- 31 July 2019
- journal article
- research article
- Published by SAGE Publications in Cephalalgia
- Vol. 39 (14) , 1745-1752
Abstract
Calcitonin gene-related peptide (CGRP) is a neuronal transmitter present in intracranial sensory nerves, where it is involved in migraine pathophysiology as well as other biological functions. Recently, the fully human monoclonal antibody erenumab (AMG 334), which targets the canonical calcitonin gene-related peptide receptor, showed significant prophylactic efficacy and favourable safety in phase II and III clinical trials for episodic and chronic migraine and is now approved for migraine prevention in several countries. Given that calcitonin gene-related peptide can mediate vasodilation, we investigated the effect of erenumab on vasoactive responses in the presence or absence of various vasodilatory and vasocontractile mediators in a model using isolated human cerebral and meningeal arteries. Ring segments of human isolated cerebral and meningeal arteries were mounted in a sensitive myograph. On arterial segments pre-contracted with 30 mM potassium chloride, vasoactive responses to calcitonin gene-related peptide were studied in the presence of different concentrations of erenumab. At the maximal tested inhibitory concentration of erenumab (100 nM), functional arterial relaxation in response to nicardipine or substance P, and the contractile responses to sumatriptan and dihydroergotamine were examined. 30 mM potassium chloride produced a stable contraction of the vessel segments and calcitonin gene-related peptide induced a concentration-dependent relaxation. We observed that (i) erenumab had no direct contractile or relaxant effects per se (by itself), (ii) pre-treatment with erenumab antagonized the calcitonin gene-related peptide-induced relaxation in a competitive manner, (iii) the relaxant responses to nicardipine or substance P were unaffected in the presence of erenumab and (iv) the contraction induced by sumatriptan or dihydroergotamine was not modified by erenumab. Our findings demonstrate that erenumab, while not associated with vasoactive properties per se, specifically inhibits calcitonin gene-related peptide-induced relaxation of cranial arteries without impacting vasodilatory responses or contractile responses of endogenous or pharmacological vasoactive compounds.Keywords
Funding Information
- Hjärt-Lungfonden
This publication has 29 references indexed in Scilit:
- Calcitonin Gene-Related Peptide: Physiology and PathophysiologyPhysiological Reviews, 2014
- Differentiation of Nerve Fibers Storing CGRP and CGRP Receptors in the Peripheral Trigeminovascular SystemThe Journal of Pain, 2013
- Magnetic resonance angiography of intracranial and extracranial arteries in patients with spontaneous migraine without aura: a cross-sectional studyThe Lancet Neurology, 2013
- Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglionNeuroscience, 2010
- Effect of the calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant in human cranial arteriesCephalalgia, 2010
- Pharmacokinetics and Brain Uptake of a Genetically Engineered Bifunctional Fusion Antibody Targeting the Mouse Transferrin ReceptorMolecular Pharmaceutics, 2009
- CGRP blockers in migraine therapy: where do they act?British Journal of Pharmacology, 2008
- Characterisation of CGRP receptors in the human isolated middle meningeal arteryLife Sciences, 2006
- Characterisation of CGRP receptors in human and porcine isolated coronary arteries: Evidence for CGRP receptor heterogeneityEuropean Journal of Pharmacology, 2006
- Differential expression of α-CGRP and β-CGRP by primary sensory neurons and enteric autonomic neurons of the ratNeuroscience, 1988